HK Stock Market Move | INNOGEN-B(02591) fell more than 5% during trading hours, with an expected annual loss of approximately 341.4 million yuan, and an increase in research and development expenses during the year.

INNOGEN-B (02591) fell by more than 5% during trading hours. As of the time of writing, it has fallen by 2.17% to 21.62 Hong Kong dollars, with a turnover of 39.821 million Hong Kong dollars. On the news front, on March 18, INNOGEN-B issued an announcement that despite the commercialization of the core product, exenatide , used for the treatment of type 2 diabetes in China and Macau, the Group achieved revenue of approximately 131.5 million yuan in the 2025 fiscal year (2024: zero). The Group expects to incur a loss of approximately 341.4 million yuan in the current year, while in the fiscal year ending December 31, 2024, a loss of approximately 174.7 million yuan was incurred. The announcement stated that the increase in losses this year was mainly due to an increase in research and development expenses of approximately 103.3 million yuan, mainly due to the increase in expenses related to the life cycle management and clinical development of exenatide , including preclinical research, clinical trials, and process optimization expenses for phase IIb/III clinical trials in China for the treatment of obesity and overweight, as well as phase II clinical research in Australia; and an increase in sales and distribution expenses of approximately 174.3 million yuan, mainly attributed to increased marketing and promotion expenses after the commercialization of exenatide , and an increase in employee welfare expenses due to the expansion of the sales team to support market development.